Rosario Menéndez1, Pedro Pablo España2, Emilio Pérez-Trallero3, Ane Uranga2, Raul Méndez4, Catia Cilloniz5, José María Marimón3, Isabel Cifuentes6, Cristina Méndez6, Antoni Torres7. 1. H. Universitario y Politécnico la Fe, Valencia, Spain; Biomedical Research Center Network for Respiratory Diseases (CIBERES), Madrid, Spain. Electronic address: rosmenend@gmail.com. 2. H. Galdakao-Usansolo, Galdácano, Spain. 3. H. Universitario Donostia, San Sebastián, Spain; Biomedical Research Center Network for Respiratory Diseases (CIBERES), Madrid, Spain. 4. H. Universitario y Politécnico la Fe, Valencia, Spain. 5. H. Clinic, Barcelona, Spain. 6. Pfizer S.L.U., Madrid, Spain. 7. H. Clinic, Barcelona, Spain; Biomedical Research Center Network for Respiratory Diseases (CIBERES), Madrid, Spain. Electronic address: atorres@clinic.ub.es.
Abstract
BACKGROUND: Streptococcus pneumoniae serotypes distribution in community-acquired pneumonia (CAP) requiring hospitalization in adults after introduction of PCV13 in children is not well known. Our aim was to evaluate the distribution of serotypes in pneumococcal pneumonia according to risk factors and comorbidity conditions after the introduction of PCV13 in children in 2010. METHODS: A prospective study from 2011 to 2014 was performed in immunocompetent adults hospitalized with CAP in 3 Spanish hospitals. Microbiological confirmation was obtained using a serotype specific urinary antigen detection test (UAD test), Binax Now and conventional cultures. RESULTS: 1258 adults were enrolled and pneumococcal pneumonia (invasive disease in 17.7%) was confirmed in 368 (29.3%) and 17.6% of the any-cause CAP were caused by PVC13 serotypes (3.5% PCV7 serotypes). Around 60% of pneumococcal CAP were caused by PCV13 serotypes (74.6% in invasive episodes vs 57.4% in non-invasive ones). The most prevalent serotypes in invasive disease were 1, 3, 7F, 19A and 14. No significant differences were observed in the distribution of PCV13 serotypes across the study periods. Regarding comorbidity, the rate of PCV13 serotypes was similar among them, and it was slightly higher in those with no underlying conditions. CONCLUSIONS: Serotypes included in PCV13 caused a significant proportion of CAP in adults with underlying conditions and in healthy adults, with no significant changes in cases due to PCV7 or PCV13 from 2011 to 2014, suggesting an insufficient indirect protection from childhood vaccination. Strategies for implementing pneumococcal vaccination of adults are encouraged to reduce the incidence of pneumococcal episodes.
BACKGROUND:Streptococcus pneumoniae serotypes distribution in community-acquired pneumonia (CAP) requiring hospitalization in adults after introduction of PCV13 in children is not well known. Our aim was to evaluate the distribution of serotypes in pneumococcal pneumonia according to risk factors and comorbidity conditions after the introduction of PCV13 in children in 2010. METHODS: A prospective study from 2011 to 2014 was performed in immunocompetent adults hospitalized with CAP in 3 Spanish hospitals. Microbiological confirmation was obtained using a serotype specific urinary antigen detection test (UAD test), Binax Now and conventional cultures. RESULTS: 1258 adults were enrolled and pneumococcal pneumonia (invasive disease in 17.7%) was confirmed in 368 (29.3%) and 17.6% of the any-cause CAP were caused by PVC13 serotypes (3.5% PCV7 serotypes). Around 60% of pneumococcal CAP were caused by PCV13 serotypes (74.6% in invasive episodes vs 57.4% in non-invasive ones). The most prevalent serotypes in invasive disease were 1, 3, 7F, 19A and 14. No significant differences were observed in the distribution of PCV13 serotypes across the study periods. Regarding comorbidity, the rate of PCV13 serotypes was similar among them, and it was slightly higher in those with no underlying conditions. CONCLUSIONS: Serotypes included in PCV13 caused a significant proportion of CAP in adults with underlying conditions and in healthy adults, with no significant changes in cases due to PCV7 or PCV13 from 2011 to 2014, suggesting an insufficient indirect protection from childhood vaccination. Strategies for implementing pneumococcal vaccination of adults are encouraged to reduce the incidence of pneumococcal episodes.
Authors: Sun Jin Kim; Yoo Jung Jeong; Jong Hun Kim; Young Kyung Yoon; Jang Wook Sohn; Moon Hee Nahm; Min Ja Kim Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: P Llinares; M C Fariñas; F Arnaíz de Las Revillas; D Sousa; C Ardunay; C García-Vidal; M Montejo; R Rodríguez-Álvarez; J Pasquau; E Bouza; J A Oteo; C Balseiro; C Méndez; N Lwoff Journal: Rev Esp Quimioter Date: 2020-07-22 Impact factor: 1.553
Authors: Loreto Arias Fernández; Jacobo Pardo Seco; Miriam Cebey-López; Ruth Gil Prieto; Irene Rivero-Calle; Federico Martinon-Torres; Ángel Gil de Miguel; F Martinón-Torres; D Vargas; E Mascarós; E Redondo; J L Díaz-Maroto; M Linares-Rufo; A Gil; J Molina; D Ocaña; I Rivero-Calle Journal: BMC Infect Dis Date: 2019-11-15 Impact factor: 3.090
Authors: Rosa Prato; Francesca Fortunato; Maria Giovanna Cappelli; Maria Chironna; Domenico Martinelli Journal: BMJ Open Date: 2018-03-25 Impact factor: 2.692
Authors: María Del Mar García-Suárez; Irene González-Rodríguez; María Dolores Cima-Cabal; Jose Enrique Yuste; Fernando Vazquez; Enrique Santiago Journal: Diagnostics (Basel) Date: 2019-11-18